Market News AIOpen the app

Citizens analyst Reni J. Benjamin kept a positive rating on BeOne Medicines and raised the price target to $463.

OpinionRead the original at moomoo.com
Good for ONC

BeOne Medicines kept an analyst's Market Outperform rating, and the analyst raised the share target. That is favorable analyst opinion, but the story reports no new company results.

ONC · BeOne Medicines

AI read · Good for ONC

The AI's read

The higher target signals the analyst sees more room for BeOne Medicines' shares. The story reports an analyst's opinion, not new sales, drug results, or company forecasts, so the evidence is limited.

Get alerts for ONC

Follow BeOne Medicines (ONC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ONC
Free on the App Store and Google Play, or on the web.